Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Bitcoin ETF (BITO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

ProShares Bitcoin ETFTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

ProShares Bitcoin ETF vs Regeneron Pharmaceuticals Inc — how do they compare? ProShares Bitcoin ETF trades at $8.77, while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while ProShares Bitcoin ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.

BITOREGN
Sector
Crypto-linkedHealth
52-Week High
$22.93$812.27
52-Week Low
$7.98$542.52
Market Cap
$68.79B
Enterprise Value
$62.74B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Bitcoin ETF

BITO trades at $8.44, down 2.65% today amid bearish technical signals with 12 sell indicators versus 4 buy signals. The ETF faces challenges with declining distributions and negative sentiment as crypto markets struggle. Recent dividend payments of $0.01-$0.02 per share provide limited offset to the fund's 24.26% five-year decline.

The outlook remains cautious with structural costs and Bitcoin correlation concerns weighing on performance. Key risks include management fee drag, distribution volatility, and crypto market exposure. Investors should monitor fee structure efficiency and Bitcoin market stability for potential recovery catalysts.

Regeneron Pharmaceuticals Inc

Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.

The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Bitcoin ETF

BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.

Read more on BITO

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN